086450 — DongKook Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for DongKook Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	559,103	594,193	661,647	730,994	812,166
Cost of Revenue
Gross Profit	337,410	350,260	379,826	410,781	447,896
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	474,370	530,974	588,994	664,120	731,746
Operating Profit	84,733	63,219	72,654	66,873	80,420
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	80,031	69,754	68,632	60,838	84,738
Provision for Income Taxes
Net Income After Taxes	57,880	52,916	54,757	48,871	62,336
Minority Interest
Net Income Before Extraordinary Items
Net Income	55,925	50,345	52,896	47,175	61,219
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	55,925	50,345	52,896	47,175	61,219
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,251	1,109	1,172	1,041	1,367
Dividends per Share